ClinicalTrials.gg
Status unknownNCT03609905AMSC_UCUpdated Sep 2, 2020

Adipose Mesenchymal Stem Cells (AMSC) for Treatment of Ulcerative Colitis

A Phase 1/2 interventional study of Adipose-cord mesenchymal stromal cells (A-MSCs) and Conventional drugs in Ulcerative Colitis (UC), sponsored by Liaocheng People's Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-09-02.

Sponsored by Liaocheng People's Hospital · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 184 studies in Colitis, Ulcerative with a site in China — 73 open to participants now, 96 under way, 25 of them phase 3. Colitis, Ulcerative · China.

Planned enrollment
103rd of 136
50 · median 121
Started
2018
with 11 others
Phase 1/2
7 of 184
2 open now
Registered
36th of 184
by date

Among the 184 studies in Colitis, Ulcerative with a site in China, this one is the 103rd largest by planned enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2018, is one of 7 in phase 1/2, and was the 36th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

73 of the 184 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Colitis, Ulcerative with a site in China, or all of them as a file.
02

Study summary

Ulcerative colitis is a form of inflammatory bowel disease characterized by diffuse inflammation of the colonic mucosa. It affects the rectum and extends proximally along a variable length of the colon. Ulcerative colitis is a chronic condition with a relapsing remitting course. Mesenchymal stem cells (MSCs) are a subset of adult stem cells residing in many tissues, including bone marrow (BM), adipose tissue, umbilical cord blood. Recent experimental findings have shown the ability of MSCs to home to damaged tissues and to produce paracrine factors with anti-inflammatory properties, potentially resulting in reduction of inflammation and functional recovery of the damaged tissues. The purpose of our study is to evaluate safety and efficacy of the intracolonic injection by using a colonoscope of allogeneic adipose MSCs in patients with moderate active ulcerative colitis.

03

Conditions studied

  • Ulcerative Colitis (UC)

Browse trials for

Keywords

  • ulcerative colitis (UC)
  • mesenchymal stem cells(MSC)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18-65 years old
  • Diagnosis of ulcerative colitis diagnosed at least 6 months earlier
  • Moderate or severe activity defined by a Mayo score
  • No serious infection, chronic diseases, diabetes and tuberculosis
  • Unefficient by using 5-ASA, or azathioprine
  • Written informed consents were obtained from all subjects
  • Capable of good communication with researchers and follow the entire test requirements
  • Negative pregnancy test for women of (from menarche to menopause)

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women or cognitively impaired adults
  • History of malignant disease
  • Infectious colitis
  • Patients with known allergies to culture medium
  • Patients having participated in clinical trials with any drug within 1 month prior to enrolment in this study
  • Patients with suspicion of Crohn's enterocolitis, indeterminate colitis, ischaemic colitis, radiation colitis, diverticular disease associated colitis, or microscopic colitis
  • Patients with previous colectomy
  • Positive to one or more of the infectious disease panel
  • Treatment with surgery or biological treatment (infliximab or adamizumab) or Cyclosporine or tacrolimus or mycophenolate in the 8 weeks prior to inclusion in the study
  • Presence of severe concomitant diseases
  • Patients with clostridium difficult or cytomegalovirus infection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Intervention group

    interventions: The MSCs of 5×10\*7 will be given in different sites within colonic submucosa at a total 100 ml with the use of the colonoscope. Once every week,a total of two times. Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used

    Biological: Adipose-cord mesenchymal stromal cells (A-MSCs) · Other: Conventional drugs

  • Other
    Control group

    interventions:Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used

    Other: Conventional drugs

Interventions

  • BiologicalAdipose-cord mesenchymal stromal cells (A-MSCs)

    A-MSCs 5 x 10\~7 diluted on 100 mL of normal saline

  • OtherConventional drugs

    5-amino-salicylic acid or glucocorticoid

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Endoscopic Score (as Measured by Ulcerative Colitis Endoscopic Index of Severity)

    Ulcerative Colitis Endoscopic Index of Severity (UCEIS) is defined as Ulcerative Colitis Endoscopic Index of Severity, with higher scores indicating more severe disease

    Time frame: Baseline, 8 weeks

Secondary outcomes

  1. Change from Baseline in clinical response (CDAI points)

    CDAI is defined as Clinical Disease Activity Index

    Time frame: Baseline, 8 weeks

  2. To evaluate the quality of life index, Short Inflammatory Bowel Disease Questionnaire (SIBDQ)

    The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is a health-related quality of life (HRQoL) tool measuring physical, social, and emotional status. It includes 10-item form of questions. Each question is scored on a Likert scale from 1 (worst) to 7 (best), scores from each item are summed to produce a total score, increased more than 3 scores were considered remission.

    Time frame: Baseline, 8 weeks

  3. Histologic Evaluation of Ulcerative Colitis

    A 10 to 20 centimeter (cm) biopsy sample of inflamed mucosal tissue was taken from the worst affected area and scored using the Riley Index. The Riley Index is a histologic scoring system for the assessment of the activity and severity of ulcerative colitis, ranging from 0 to 24. It consists of 6 histologic features (acute inflammatory cell infiltrate, crypt abscesses, mucin depletion, surface epithelial integrity, chronic inflammatory cell infiltrate, and crypt architectural irregularities), all scored on a 4-point scale (higher scores indicate more severe disease).

    Time frame: Baseline, 8 weeks

  4. Immune response in ulcerative colitis.

    A number of soluble mediators are detected, including proinflammatory cytokines (TNF, IFN-γ, IL-6.) and anti-inflammatory cytokines (IL-10, IL-4.).

    Time frame: Baseline, 1, 4, 8 weeks

  5. Incidence of Treatment Adverse.

    An AE was any untoward medical occurrence in a participant

    Time frame: Baseline, 1, 4, 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Liaocheng city people's hospital
    Liaocheng, Shandong 0635, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2018 (actual). Primary completion is estimated for Jun 2021, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2018
First posted
Aug 1, 2018
StartActual
Jul 1, 2018
Primary completionEst.
Jun 1, 2021
CompletionEst.
Dec 1, 2021
Last update
Sep 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03609905
Lead sponsor
Liaocheng People's Hospital
Responsible party
peng yan (Chief of gastroenterology, Liaocheng People's Hospital) — Principal investigator
First posted
Aug 1, 2018
Start date
Jul 1, 2018
Primary completion
Jun 1, 2021 (estimated)
Completion
Dec 1, 2021 (estimated)
Last update
Sep 2, 2020

Study contacts

Shaoda Ren, Ph.D.
Contact
zslrsd@163.com
86-0635-8272202
Peng Yan, MD
study chair · Liaocheng People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion